Abstract | BACKGROUND: OBJECTIVE: To assess disability and magnetic resonance imaging-related outcomes in relapsing multiple sclerosis patients from a Phase 2 study of fingolimod 10 or more years after randomization and to compare outcomes in patients who had a higher fingolimod exposure versus those with a lower fingolimod exposure. METHODS: ACROSS was a cross-sectional follow-up study of patients originally enrolled in a Phase 2 fingolimod proof-of-concept study (NCT00333138). Disability and magnetic resonance imaging-related outcomes were assessed in patients grouped according to fingolimod treatment duration, based on an arbitrary cut-off: ≥8 years (high exposure) and <8 years (low exposure). RESULTS: Overall, 175/281 (62%) patients participated in ACROSS; 104 (59%) of these were classified "high exposure." At 10 years, patients in the high-exposure group had smaller increases in Expanded Disability Status Scale (+0.55 vs. +1.21), and lower frequencies of disability progression (34.7% vs. 56.1%), wheelchair use (4.8% vs. 16.9%), or transition to secondary progressive multiple sclerosis (9.6% vs. 22.5%) than those in the low-exposure group. The high-exposure patients also had less progression in most magnetic resonance imaging-related outcomes. CONCLUSION: After 10 years of fingolimod treatment, disability progression was lower in the high-exposure group than in the low-exposure group.
|
Authors | T Derfuss, J Sastre-Garriga, X Montalban, M Rodegher, J Wuerfel, L Gaetano, D Tomic, A Azmon, C Wolf, L Kappos |
Journal | Multiple sclerosis journal - experimental, translational and clinical
(Mult Scler J Exp Transl Clin)
2020 Jan-Mar
Vol. 6
Issue 1
Pg. 2055217320907951
ISSN: 2055-2173 [Print] United States |
PMID | 32284874
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2020. |